CLINICAL TRIALS PROFILE FOR ARSENIC TRIOXIDE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for arsenic trioxide
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Dosage | NCT00225992 ↗ | Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) | Terminated | Oncology Specialties, Alabama | Phase 2 | 2004-02-01 | In this phase II study besides evaluating for safety, the primary efficacy parameter is to evaluate the incidence of patients who have had a response to Trisenox by evidence of increased blood counts (red, white, or platelets) and/or by decrease or transfusion dependency. The secondary efficacy parameter is the assessment of the tolerability of the new dosing schedule. Arsenic trioxide will be administered intravenously over 1 to 2 hours with a loading dose of 0.30mg/kg for days 1-5 of the first week and then twice weekly for 27 weeks for a total of 28 weeks. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for arsenic trioxide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003395 ↗ | Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | 1998-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced hematologic cancer. |
| NCT00003395 ↗ | Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | 1998-04-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced hematologic cancer. |
| NCT00003630 ↗ | Arsenic Trioxide in Treating Patients With Advanced Solid Tumors | Completed | National Cancer Institute (NCI) | Phase 1 | 1998-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced solid tumors. |
| NCT00003630 ↗ | Arsenic Trioxide in Treating Patients With Advanced Solid Tumors | Completed | Memorial Sloan Kettering Cancer Center | Phase 1 | 1998-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced solid tumors. |
| NCT00003885 ↗ | Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma | Unknown status | Our Lady of Mercy Medical Center | Phase 2 | 1997-11-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent or refractory acute leukemia, chronic myeloid leukemia, myelodysplasia, lymphoma, or myeloma. |
| NCT00003934 ↗ | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | Completed | National Cancer Institute (NCI) | Phase 3 | 1999-06-01 | This randomized phase III trial is studying tretinoin and combination chemotherapy to see how well they work compared to tretinoin, combination chemotherapy, and arsenic trioxide in treating patients with acute promyelocytic leukemia that has not been treated previously. Drugs used in chemotherapy, such as daunorubicin, cytarabine, mercaptopurine, methotrexate, and arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Tretinoin may help leukemia cells develop into normal white blood cells. It is not yet known which regimen is more effective for acute promyelocytic leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for arsenic trioxide
Condition Name
Clinical Trial Locations for arsenic trioxide
Trials by Country
Clinical Trial Progress for arsenic trioxide
Clinical Trial Phase
Clinical Trial Sponsors for arsenic trioxide
Sponsor Name
